Survival Analysis of AIDS in-patients at Joint Clinical Research Centre, Uganda
Jonathan Odwee, Makerere University
The study compares survival between ARV experienced and naaive in-patients and determine prognostic factors related to their survival. The majority of the patients were in WHO disease Stage 4. Tuberculosis was most prevalent in the ward while cryptococcal meningitis was the leading cause of death. The median survival time in the ARV group was 180 days while that of the naive was 36 days. ARV use reduced the risk of dying by a factor of 0.5 in patients in Stage 4 but did not significantly affect survival in the other stages of the disease. The older patients were 2.7 times more likely to die than the younger ones in in earlier disease stages. It is concluded that ARV patients survived longer than the naive in-patients and ARV use is a prognostic factor for Stage 4 patients. Age is a prognostic factor but only for patients in lower stages of disease.